ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 40 citations in OpenAlex.
- Evaluation of Dried Plasma Spot-Based Quantification of Glial Fibrillary Acidic Protein as a Disease-Associated Biomarker in Neuromyelitis Optica Spectrum Disorder.Annals of clinical and translational neurology · 2026Article
- Article
- Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study.The journal of prevention of Alzheimer's disease · 2026Article
- Substituting blood-based biomarkers for imaging measures in Alzheimer's disease studies: implications for sample size and bias.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Blood-based biomarkers of Alzheimer's disease: potential utility in clinical practice.Current opinion in neurology · 2026Review
- Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations.medRxiv : the preprint server for health sciences · 2026Article
- Capillary blood sampling for detecting biomarkers of Alzheimer's disease.Nature medicine · 2026Article
- A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.Nature medicine · 2026Article
- Review
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Substituting Blood-Based Biomarkers for Imaging Measures in Alzheimer's Disease Studies: Implications for Sample Size and Bias.medRxiv : the preprint server for health sciences · 2025Article
- Machine learning-assisted optimization of dietary intervention against dementia risk.Nature human behaviour · 2025Article
- Review
- A multi-omics-empowered framework for precision diagnosis and treatment of lysosomal diseases.Journal of pharmaceutical analysis · 2025Review
- Article
- Down syndrome in Africa: Challenges, opportunities, and future directions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit.Scientific reports · 2025Article
- Global multi-specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 5 countries.
Funding
Abstract
backgroundWe aimed to evaluate the precision of Alzheimer's disease (AD) and neurodegeneration biomarker measurements from venous dried plasma spots (DPS
methodsIn a discovery (n = 154) and a validation cohort (n = 115), glial fibrillary acidic protein (GFAP); neurofilament light (NfL); amyloid beta (Aβ) 40, Aβ42; and phosphorylated tau (p-tau181 and p-tau217) were measured in paired DPS
resultsAll DPS DISCUSSION: Our data suggest that measuring blood biomarkers related to AD pathology and neurodegeneration from DPS HIGHLIGHTS: A wide array of biomarkers related to Alzheimer's disease (AD) and neurodegeneration were detectable in dried plasma spots (DPS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.